Other studies have shown clinical efficacy of treatments with allogeneic NK cells activated with IL-25 or stimulated with IL-15, IL-12, and IL-186 in AML or myelodysplastic syndrome (MDS) patients. This evidence concerns the gene IL25 and myelodysplastic syndrome.